Pregnancy labeling bill
Senate Health Committee drops Sen. Tom Harkin's (D-Iowa) pregnancy labeling bill from schedule after members could not agree on language. S 2328 would have authorized FDA to require research on the use of drugs during pregnancy (1"The Pink Sheet" July 29, p. 11)...
You may also be interested in...
An additional three months of exclusivity would be awarded for a company's second round of pediatric studies under a proposed amendment to Sen. Hillary Rodham Clinton's (D-N.Y.) bill to codify FDA's mandatory pediatric study rule
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.